Breast cancers demonstrate a gradient of responsiveness to endocrine therapy according to hormone receptor status, with tumors positive for both estrogen and progesterone receptors responding most favorably. The authors hypothesized that reproductive risk factors, which are probably mediated by endogenous hormones, would also differ according to receptor status, and that tumors positive for both receptors would exhibit the highest risk. Information on risk factors was obtained from 1,154 breast cancer cases and 21,714 cancer-free controls at the Aichi Cancer Center Hospital, Nagoya, Japan between 1988 and 1992. Receptor status was known for 40% of cases. For a given risk factor, odds ratios with respect to the common control group for breast cancers of differing receptor status were compared using multiple polytomous logistic regression. Risk factors did not differ significantly according to estrogen receptor status. However, age at diagnosis/interview, occupation, age at menarche, menstrual regularity at ages 20-29 years, and cigarette smoking differed significantly or borderline significantly in effect according to progesterone receptor status. Stratification of cases according to joint estrogen and progesterone receptor status indicated that estrogen receptor status did not modify this difference in effect. This study did not support the hypothesis of a gradient of risk for reproductive factors according to hormone receptor status. The authors recommend that the finding that some risk factors differ according to progesterone receptor status should be pursued in further studies. Received for publication October 10, 1995, and accepted for publication April 7, 1997.
The clearest clinical and biologic distinctions are between tumors positive for both estrogen receptors and progesterone receptors versus tumors that are negative for both receptors (1, 2, 4, 5) . The behavior of tumors that are estrogen receptor-positive and progesterone receptor-negative is intermediate. The characterization of the small proportion of breast cancers determined to be estrogen receptor-negative, progesterone receptor-positive is controversial.
It is not yet clear whether breast cancers of differing hormone receptor status represent etiologically distinct forms of the disease with different risk factor profiles (6, 7) . Reports that have examined risk factors by estrogen receptor status or by progesterone receptor status (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) have not produced clear and consistent findings. While a more refined and possibly biologically more meaningful approach would stratify by estrogen receptor and progesterone receptor status jointly, only a few studies have done so thus far (7, 19, 22) .
The gradient of responsiveness to hormonal therapy leads to the hypothesis that estrogen receptor-positive, progesterone receptor-positive tumors would be most closely related to reproductive risk factors that are probably mediated by endogenous hormones (7, 24) , while estrogen receptor-negative, progesterone receptor-negative tumors would be unrelated to these risk factors. Receptor status-discordant tumors might exhibit intermediate risk factor profiles.
In a previous report, the authors utilized 2 years of data from an ongoing hospital-based case-control study in Japan to examine known and suspected breast cancer risk factors stratified separately by estrogen receptor and progesterone receptor status (23) . This earlier study provided some evidence that certain risk factors may differ by progesterone receptor status, but not by estrogen receptor status. The present report includes data from an additional 3 years, and it thus provides a sufficient number of cases to stratify jointly by estrogen receptor and progesterone receptor status.
MATERIALS AND METHODS
General characteristics of the study population and the data collection procedures have been described elsewhere (23, 25, 26) . Briefly, a self-administered questionnaire about life-style, reproductive, and other factors has been given routinely to first-visit outpatient adults at the Aichi Cancer Center Hospital, Nagoya, Japan. Most outpatients visited the hospital for detection or diagnosis of cancer, not for treatment. The present report is based on women who completed the questionnaire between January 1988 and December 1992.
Cases were all women diagnosed with histologically confirmed invasive breast cancer between 1988 and 1992. Controls were all women confirmed to be cancer-free by diagnostic procedures at the hospital. Cases and controls were aged 25 years or older. Women with a past history of cancer were excluded from the analysis, as were women with missing observations in at least three of four variables (age at menarche, age at menopause, age at first full-term pregnancy, and average months of breastfeeding per child) (0 cases; 13 controls). The analysis included 1,154 cases and 21,714 controls.
The presence of estrogen receptors in the breast cancer tissue was determined by the dextran-coated charcoal method during 1988-1989 (27) , and by a enzyme-linked immunoassay commercial kit (Ohtsuka Assay, Tokushima, Japan) during 1990-1992. The presence of progesterone receptors was determined by the dextran-coated charcoal method (27) . The cut-off point for receptor-positivity was 10 fmol/mg of protein for the dextran-coated charcoal assay and 5 fmol/mg of protein for the radioimmunoassay. Receptor assays could only be performed on tumors larger than around 20 mm in diameter with the dextran-coated charcoal method and larger than about 10 mm in diameter by means of the enzyme-linked immunoassay. Consequently, receptor assays were performed on only 40 percent of the cases.
All cases (receptor status known and unknown combined) were compared with controls using unconditional multiple logistic regression. Odds ratios and 95 percent confidence intervals were calculated for known and suspected breast cancer risk factors, which were included in the model simultaneously.
The multiple polytomous logistic regression model (28) , with disease status including receptor status as the response, was used to determine whether risk factors for breast cancer differed according to receptor status. This model allowed simultaneous odds ratio estimation for breast cancers of differing receptor status and a given risk factor with respect to the common control group. The Wald statistic (29) was calculated to determine the p value for the heterogeneity of the odds ratios. The null hypothesis was expressed using a linear contrast matrix, C, and the statistic was determined using
where b represents the parameters estimated in the regression and Var(b) is the corresponding covariance matrix.
The following variables were included in each model as categorical variables: age at diagnosis/interview, current occupation (housewives vs. all others), family history of breast cancer among first-degree relatives, menstrual regularity at ages 20-29 years, menopausal status, ever had a full-term pregnancy, alcohol consumption, and cigarette smoking. Included in the models as continuous variables were age at menarche, age at menopause, age at first full-term pregnancy, number of full-term pregnancies, and average months of breastfeeding per child.
All of the above categorical and continuous variables were included simultaneously in each model. For the continuous variables applying only to parous women, nulliparous women were assigned a value of zero. Because the variable "ever had a full-term pregnancy" was also included in the model, this removed the influence of nulliparity from the coefficient estimates for these continuous variables. Similarly, for the continuous variable "age at menopause," premenopausal women were assigned a value of zero.
For subjects who reported that they had stopped menstruating for reasons other than natural menopause (mainly hysterectomy), because both ovaries are generally not removed when a hysterectomy is performed in Japan, menopausal status and age at menopause were imputed using the following algorithm. If the woman stopped menstruating at or before age 50 years, she was assumed to be premenopausal. If the woman stopped menstruating after age 50 years, she was considered to be postmenopausal and was as-signed an age at menopause of the age that she stopped menstruating. Menopausal status (and age at menopause for women imputed to be postmenopausal) was imputed in this manner for 104 cases and 1,585 controls.
Further imputation of a small number of unknown values was done as follows. The women whose menopausal status was still unknown were considered to be premenopausal if their age at diagnosis/interview was less than 50 years and postmenopausal if their age at diagnosis/interview was 50 years or greater. The latter women were assigned an age at menopause of 50 years. Missing values for other continuous variables were replaced with age-stratum-specific median values. Missing values for menstrual regularity at ages 20-29 years were considered to be regular. Subjects with missing observations for alcohol consumption and cigarette smoking were considered to be neverusers.
RESULTS
The number of cases by estrogen and progesterone receptor status is shown in table 1. Estrogen receptor status was known for 458 (40 percent) of the cases; 291 (64 percent) of these cases were estrogen receptorpositive. Progesterone receptor status was known for 455 (39 percent) of the cases (three of the cases for whom estrogen receptor status was reported had no report on progesterone receptor status); 200 (44 percent) of these cases were progesterone receptorpositive. Of the 455 cases whose estrogen and progesterone receptor status were both known, 39 percent were positive for both receptors, 31 percent negative for both receptors, 25 percent estrogen receptorpositive and progesterone receptor-negative, and 5 percent estrogen receptor-negative and progesterone receptor-positive.
All cases (both receptor status known and unknown) were compared with controls in a multiple logistic regression model (table 2). Significant associations were observed between breast cancer and age at diag- nosis/interview, menstrual irregularity at ages 20-29 years, age at menopause, age at first full-term pregnancy, occupation as housewife, family history of breast cancer among first-degree relatives, and cigarette smoking. Nonsignificant associations were observed with age at menarche, and number of full-term pregnancies.
Cases with known estrogen receptor status and cases with unknown estrogen receptor status were simultaneously compared with controls using a multiple polytomous logistic regression model (data not shown). None of the risk factors in the model exhibited significant heterogeneity of odds ratios.
Estrogen receptor-positive cases and estrogen receptor-negative cases were compared simultaneously with controls (table 3) . No significant heterogeneity of odds ratios was observed for any risk factor. Table 4 shows the comparison of progesterone receptor-positive cases and progesterone receptornegative cases with controls. Breast cancer increased with age more rapidly at diagnosis/interview for progesterone receptor-positive cases than for progesterone receptor-negative cases (p value for heterogeneity of odds ratios = 0.014). The odds ratio for occupation other than housewife was elevated in progesterone receptor-positive cases (odds ratio (OR) = 1.30, 95 percent confidence interval (CI) 0.97-1.75), but was reduced in progesterone receptor-negative cases (OR = 0.79, 95 percent CI 0.61-1.01) (p value for heterogeneity of odds ratios = 0.011). Age at menarche was negatively associated with progesterone receptor-positive breast cancer (OR = 0.83 per 2 years, 95 percent CI 0.69-1.00), but positively associated with progesterone receptor-negative breast cancer (OR = * All of the variables were included simultaneously in a multiple polytomous logistic regression model. Odds ratios were adjusted for all other covariates and were derived from the regression coefficient and standard error in the multiple polytomous logistic regression model. t aOR, adjusted odds ratio; CI, confidence interval; df, degrees of freedom. % The Wald statistic p value indicates the statistical significance of differences in odds ratios for a given risk factor between ER+ and ERcases. It was calculated based on differences in parameter estimates and their covariances from the multiple polytomous logistic regression model. § Family history of breast cancer among first-degree relatives. H Risk factor included in the model as a continuous variable. The adjusted odds ratio is for a change in exposure of the magnitude of the units shown.
# Menstrual regularity at ages 20-29 years. The four case groups according to combined estrogen and progesterone receptor status were compared with the controls (table 5). Significant odds ratio heterogeneity was found for age at menarche (p = 0.015) and menstrual regularity at ages 20-29 years (p = 0.024). However, estrogen receptor status did not appear to modify the difference in effect according to progesterone receptor status for these variables or for age at diagnosis/ interview, occupation, or cigarette smoking. Thus, for example, age at menarche was negatively associated with progesterone receptor-positive breast cancer and was positively associated with progesterone receptor-negative breast cancer, regardless of estrogen receptor status. Similarly, menstrual irregularity at ages 20-29 years was positively associated with progesterone receptor-positive breast cancer and was negatively associated with progesterone receptor-negative breast cancer, regardless of estrogen receptor status. Estrogen receptor-positive, progesterone receptor-positive breast cancer showed a marked increase in odds ratios with age at diagnosis/ interview, although the confidence intervals were quite wide. Also noteworthy was a protective effect of number • All of the variables were included simultaneously in a multiple polytomous logistic regression model. Odds ratios were adjusted for all other covariates and were derived from the regression coefficient and standard error in the multiple polytomous logistic regression model.
f aOR, adjusted odds ratio; Cl, confidence interval; df, degrees of freedom. i The Wald statistic p value indicates the statistical significance of differences in odds ratios for a given risk factor among the four case groups. It was calculated based on differences in parameter estimates and their covariances from the multiple polytomous logistic regression model. of full-term pregnancies in estrogen receptor-negative, progesterone receptor-positive cases only (OR = 0.40 per full-term pregnancy, 95 percent CI 0.18-0.86).
DISCUSSION
As in our previous report on the data from 1988 -1989 (23) (a subset of the 1988-1992 data in the current report), risk factors for breast cancer varied by progesterone receptor status, but not by estrogen receptor status. In the present study, differences in association according to progesterone receptor status were observed for age at diagnosis/interview, occupation, age at menarche, menstrual regularity at ages 20-29 years, and cigarette smoking. When we stratified by estrogen receptor and progesterone receptor status jointly, none of these differences were found to be modified by estrogen receptor status.
Overall, our results were not consistent with the hypothesis of a gradient of risk for reproductive risk factors according to hormone receptor status. Estrogen receptorpositive, progesterone receptor-positive breast cancer was most closely related to these risk factors, and estrogen receptor-negative, progesterone receptor-negative breast cancer was unrelated to the risk factors. According to our hypothesis, early age at menarche, menstrual regularity at ages 20-29 years, late age at menopause, late age at first full-term pregnancy, fewer full-term pregnancies, and less breastfeeding should have been most closely associated with estrogen receptor-positive, progesterone receptor-positive breast cancer (24, 30) . With the exception of early age at menarche and menstrual regularity, no such pattern was observed (table 5) .
Potter et al. (7) have interpreted their prospective cohort study of breast cancer risk factors by joint estrogen and progesterone receptor status to indicate that it is progesterone receptor-positive breast cancer, independent of estrogen receptor status, that is related to endogenous hormonal risk factors. Our results for age at menarche are consistent with this hypothesis. Moreover, the pattern of menstrual factors is remarkably similar. In both studies, age at menarche was associated with only estrogen receptor-positive, progesterone receptorpositive breast cancer, and age at menopause was associated with increased risk of estrogen receptor-positive, progesterone receptor-negative breast cancer. However, our results for menstrual regularity at ages 20-29 years were in the opposite direction to those expected under the hypothesis.
Potter et al. noticed that progesterone receptor-positive breast cancer is most associated with family history (7). Our results, which found family history to not be associated with estrogen receptor-positive, progesterone receptor-negative breast cancer, are consistent with this finding (tables 4 and 5), although there was no evidence for a statistically significant difference in effect between progesterone receptor-positive and progesterone receptor-negative breast cancer.
Potter et al. also hypothesized estrogen receptornegative, progesterone receptor-negative breast cancer to have the strongest association with alcohol consumption (7). We observed no significant associations between any of the four receptor status subgroups and alcohol consumption. Estrogen receptor-negative, progesterone receptor-negative breast cancer actually had the strongest inverse association (OR = 0.68, 95 percent CI 0.44-1.05) (table 5) .
Age has been reported to be a stronger risk factor for estrogen receptor-positive breast cancer than for estrogen receptor-negative breast cancer (6) . Our results were consistent with this finding (table 3) , although the difference in odds ratios between the two case groups was not statistically significant. Our data suggest that progesterone receptor-positivity is more closely associated with age than is estrogen receptorpositivity.
Most studies have found cigarette smoking to increase the risk of breast cancer only slightly, if at all (31) . We observed only a slightly raised odds ratio for ever-smoking among all breast cancer cases combined (OR = 1.25) (table 2). After stratifying by progesterone receptor status, however, the odds ratio elevation was found to be confined to progesterone receptorpositive breast cancer (OR = 1.73), and was not observed in progesterone receptor-negative breast cancer (OR = 1.06) (table 4). Thus, the weak association between cigarette smoking and breast cancer generally found in previous studies may have been a result of not taking hormone receptor status into account.
In this study, only about 40 percent of cases had known receptor status, leaving open the possibility of selection bias, the main selection factor being tumor size. Because there were no significant risk factor differences between cases with receptor status known and cases with receptor status unknown, this argues against substantial bias in the selection of cases for receptor status measurement. It is also reassuring that the distribution of cases by receptor status was roughly similar to that seen in a large study carried out in 10 Japanese hospitals (32) . For a selection bias to have influenced the essential results of this study, cases with a given risk factor would have had to have been selected differentially across the four hormone receptor status subgroups, which seems unlikely. Overall, the odds ratios of reproductive factors for receptorunknown group were similar to those for estrogen receptor-positive and progesterone receptor-positive cases, as would be expected (table 5) .
In summary, the results of this study did not support the hypothesis of a gradient of risk for reproductive risk factors according to hormone receptor status. Nevertheless, our finding that some risk factors may differ for progesterone receptor-positive versus progesterone receptor-negative breast cancer, through a yet to be understood mechanism, is intriguing and should be pursued in future studies.
